Download Free Medical IMAGING BREAST CANCER PowerPoint Presentation

IMAGING BREAST CANCER PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Radiology and Imaging, which is titled "IMAGING IN BREAST CANCER", to know about breast cancer imaging.

Tags : Radiology, Imaging, breast cancer

Published on : Aug 02, 2021 | Views : 2898 | Downloads : 8

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

IMAGING IN BREAST CANCER Dr. Fahad Shafi PG 1ST YEAR
Slide 2-

Breast Cancer……. Worldwide, breast cancer is the most common invasive cancer in women.Breast cancer comprises 22.9% of invasive cancers in women and 16% of all female cancers. In 2012, it comprised 25.2% of cancers diagnosed in women, making it the most common female cancer.]
Slide 3-

GLOBAL TREND OF BREAST CANCER The incidence of breast cancer in women has continued to rise. The rate of increase has slowed recently, however, with the exception of in situ breast cancer. Breast cancer death rates have decreased since the early 1990s, with decreases of 2.5% per year among white women. Decreased breast cancer deaths have been attributed in part to breast cancer screening, adjuvant chemotherapy, and adoption of healthy standard of living Randomized, population- controlled breast cancer screening trials using mammography have shown an approximately 30% reduction in breast cancer deaths in the women invited to screening compared to women in the control group. Because of this data, the American Cancer Society recommends annual screening mammography for women age 40 years and older.
Slide 4-

Risk Factors Female Older age Personal history of breast cancer Family History Early menarche Late menopause Nulliparity First birth after age 30 Atypical ductal hyperplasia BRCA1, BRCA2 Radiation exposure Lobular carcinoma in situ Li fraumeni ,Cowden and Ataxia Telangiectasia CHRT
Slide 5-

Signs and Symptoms of Breast Cancer Breast lump Nipple discharge (new and spontaneous) Bloody Serosanguineous Serous but copious New nipple inversion Skin retraction or tethering Peau d’orange Nothing (cancer detected on screening mammography)
Slide 6-

IMAGING TECHNIQUES MAMMOGRAPHY ULTRASONOGRAPHY MRI PET CT
Slide 7-

MAMMOGRAPHY VIEWS Craniocaudal CC Mediolateral oblique MLO Mediolateral ML Lateral-medial LM Laterally exaggerated craniocaudal XCCL Medially exaggerated craniocaudal XCCM Cleavage view CV Rolled view laterally RL Rolled view medially RM From below FB
Slide 8-

Views Used to Confirm or Exclude a Lesion (Commonly a One-View-Only Finding Lateral view Spot compression Spot compression magnification Rolled views (with or without spot compression or magnification) Repeat the same view Step oblique views Ultrasound
Slide 9-

Mammography - Breast Imaging Lexicon Breast Composition Mass Architectural distortion Asymmetries Calcifications Associated features Special cases
Slide 10-

Breast Composition In the BI-RADS edition 2013 the assignment of the breast composition is changed into a, b, c and d-categories followed by a description: a- The breast are almost entirely fatty. Mammography is highly sensitive in this setting. b- There are scattered areas of fibroglandular density. The term density describes the degree of x-ray attenuation of breast tissue but not discrete mammographic findings. c- The breasts are heterogeneously dense, which may obscure small masses. Some areas in the breasts are sufficiently dense to obscure small masses. d- The breasts are extremely dense, which lowers the sensitivity of mammography.
Slide 11-

ppt slide no 11 content not found
Slide 12-

Mass A 'Mass' is a space occupying 3D lesion seen in two different projections. If a potential mass is seen in only a single projection it should be called a 'asymmetry' until its three-dimensionality is confirmed. Shape: oval (may include 2 or 3 lobulations), round or irregular Margins: circumscribed, obscured, microlobulated, indistinct, spiculated Density: high, equal, low or fat-containing
Slide 13-

ppt slide no 13 content not found
Slide 14-

ppt slide no 14 content not found
Slide 15-

Here a hyperdense mass with an irregular shape and a spiculated margiN.Notice the focal skin retraction. This was reported as BI-RADS 5 and proved to be an invasive ductal carcinoma.
Slide 16-

Architectural distortion The term architectural distortion is used, when the normal architecture is distorted with no definite mass visible. This includes thin straight lines or spiculations radiating from a point, and focal retraction, distortion or straightening at the edges of the parenchyma. The differential diagnosis is scar tissue or carcinoma. Architectural distortion can also be seen as an associated feature.For instance if there is a mass that causes architectural distortion, the likelihood of malignancy is greater than in the case of a mass without distortion.
Slide 17-

Notice the distortion of the normal breast architecture on oblique view (yellow circle) and magnification view. A resection was performed and only scar tissue was found in the specimen
Slide 18-

Asymmetries
Slide 19-

Here an example of a focal asymmetry seen on MLO and CC- view. Local compression views and ultrasound did not show any mass
Slide 20-

Here an example of global asymmetry. In this patient this is not a normal variant, since there are associated features, that indicate the possibility of malignancy like thickened septa and subtle nipple retraction. Ultrasound (not shown) detected multiple small masses that proved to be adenocarcinoma. The PET-CT shows diffuse infiltrating carcinoma
Slide 21-

Asymmetry versus Mass All types of asymmmetry have different border contours than true masses and also lack the conspicuity of masses.Asymmetries appear similar to other discrete areas of fibroglandulair tissue except that they are unilateral, with no mirror-image correlate in the opposite breast. An asymmetry demonstrates concave outward borders and usually is interspersed with fat, whereas a mass demonstrates convex outward borders and appears denser in the center than at the periphery.
Slide 22-

Calcifications
Slide 23-

ppt slide no 23 content not found
Slide 24-

ppt slide no 24 content not found
Slide 25-

Distribution of calcifications The arrangement of calcifications, the distribution, is at least as important as morphology. These descriptors are arranged according to the risk of malignancy: Diffuse: distributed randomly throughout the breast. Regional: occupying a large portion of breast tissue > 2 cm greatest dimension Grouped (historically cluster): few calcifications occupying a small portion of breast tissue: lower limit 5 calcifications within 1 cm and upper limit a larger number of calcifications within 2 cm. Linear: arranged in a line, which suggests deposits in a duct. Segmental: suggests deposits in a duct or ducts and their branches.
Slide 26-

ppt slide no 26 content not found
Slide 27-

Morphology: some are coarse heterogenous and some look more like fine pleomorphic Distribution: Some calcifications are in a group ( <2cm) and some are in a regional distribution ( >2cm), but not in a segmental or linear arrangement
Slide 28-

Associated features Associated features are things that are seen in association with suspicious findings like masses, asymmetries and calcifications. Associated features play a role in the final assessment. For instance a BI-RADS 4-mass could get a BI- RADS 5 assessment if seen in association with skin retraction
Slide 29-

ppt slide no 29 content not found
Slide 30-

Special cases Special cases are findings with features so typical that you do not need to describe them in detail, like for instance an intramammary lymph node or a wart on the skin
Slide 31-

DIAGNOSTIC VERSUS SCREENING MAMMOGRAPHY Screening Asymptomatic women CC and MLO mammograms Films taken and patient released Diagnostic Symptomatic women or mammographic finding CC and MLO mammograms Additional mammograms tailored to the problem With or without breast ultrasound Radiologist on-site to guide workup
Slide 32-

SAFETY OF MAMMOGRAPHY
Slide 33-

BREAST ULTRASOUND Ultrasound is a useful adjunct to mammography for the diagnosis and management of benign and malignant breast disease. Hand-held units should include a linear array, high-frequency transducer operating at a frequency of 7.5 to 10 MHz or greater, which provides good tissue penetration to 4 or 5 cm
Slide 34-

Normal Ultrasound Appearance of Breast Tissue Normal Ultrasound Appearance of Breast Tissue* Skin: 2- to 3-mm echogenic superficial line Fat: hypoechoic (exception: fatty hilum in lymph nodes) Glandular tissue: echogenic Breast ducts: hypoechoic tubular structures, oval in cross-section Nipple: hypoechoic, can shadow intensely Cooper ligaments: thin echogenic lines Ribs: hypoechoic, round periodic structures at the chest wall
Slide 35-

ppt slide no 35 content not found
Slide 36-

American College of Radiology BI- RADS® Ultrasound Lexicon Descriptors Shape oval round irregular Margin circumscribed angular indistinct microlobulated
Slide 37-

Echopattern anechoic hyperechoic complex isoechoic hypoechoic Posterior acoustic enhancement no enhancement shadowing combined
Slide 38-

Effect on surrounding tissues no effect duct changes cooper ligament changes edema architectural distortion skin thickening skin retraction/irregularity
Slide 39-

Calcifications none macrocalcifications >0.5mm microcalcifications <0.5mm
Slide 40-

Suspicious Ultrasound Characteristics of Solid Breast Masses Taller than wide Acoustic shadowing Spiculation Microlobulation Microcalcifications Duct extension Branch pattern Angular margins Markedly hypoechoic (in comparison to fat)
Slide 41-

ppt slide no 41 content not found
Slide 42-

COLOR DOPPLER, POWER DOPPLER, ULTRASOUND CONTRAST AGENTS, THREE-DIMENSIONAL IMAGING, AND ELASTOGRAPHY Color Doppler imaging does not always detect increased flow in breast cancer, and there is overlap between benign and malignant blood flow patterns. Attempts to increase the sensitivity of ultrasound for detecting blood flow with power Doppler improved these results, but not enough to advocate its use as a screening mechanism
Slide 43-

CE US AND 3D US The use of contrast agents has been proposed as a means of increasing the ability of ultrasound vascular imaging techniques to detect small increases in vascular density. Three-dimensional gray-scale ultrasound, though promising, is also still being developed.
Slide 44-

ELASTOGRAPHY Using ultrasound, elastography shows cancers, which are generally stiffer than normal soft breast tissue, as darker and larger than on the B-mode gray-scale ultrasound. Benign masses are soft and less stiff than cancers. The elastogram shows benign masses as smaller on elastography than on B-mode grayscale images
Slide 45-

Final Assessment Categories BI-RADS 0 Need Additional Imaging Evaluation and/or Prior Mammograms For Comparison When additional imaging studies are completed, a final assessment is made.
Slide 46-

This patient presented with a mass on the mammogram at screening, which was assigned as BI- RADS 0 (needs additional imaging evaluation). Additional ultrasound demonstrated that the mass was caused by an intramammary lymph node. The final assessment is BI-RADS 2 (benign finding).
Slide 47-

BI-RADS 1 There is nothing to comment on
Slide 48-

ppt slide no 48 content not found
Slide 49-

BI-RADS 2 Follow up after breast conservative surgery Involuting, calcified fibroadenomas Multiple large, rod-like calcifications Intramammary lymph nodes Vascular calcifications Implants Architectural distortion clearly related to prior surgery. Fat-containing lesions such as oil cysts, lipomas, galactoceles and mixed-density hamartomas. They all have characteristically benign appearances, and may be labeled with confidence.
Slide 50-

ppt slide no 50 content not found
Slide 51-

BI-RADS Category 2: Mass seen on mammogram proved to be a cyst.
Slide 52-

BI-RADS 3 Probably Benign Finding Initial Short-Interval Follow-Up Suggested: It is not expected to change over the follow-up interval, but the radiologist would prefer to establish its stability. Lesions appropriately placed in this category include:
Slide 53-

Lesions appropriately placed in this category include: On Mammography Nonpalpable, Noncalcified circumscribed solid mass Focal asymmetry Solitary group of punctuate calcifications On US with robust evidence to suggest Typical fibroadenoma Isolated complicated cyst Clustered microcysts
Slide 54-

ppt slide no 54 content not found
Slide 55-

Here a non-palpable sharply defined mass with a group of punctate calcifications. The mass was categorized as BI-RADS 3.
Slide 56-

Follow-up at 6, 12 and 24 months showed no change and the final assessment was changed into a Category 2.
Slide 57-

If a BI-RADS 3 lesion shows any change during follow up, it will change into a BI-RADS 4 or 5 and biopsy should be performed.
Slide 58-

BI-RADS 4 Suspicious Abnormality - Biopsy Should Be Considered BI-RADS 4 has a wide range of probability of malignancy (2 – 95%).
Slide 59-

CATEGORY 4A Partially circumscribed mass, suggestive of (atypical) fibroadenoma Palpable, solitary, complex cystic and solid cyst Probable abscess
Slide 60-

Category 4b Group amorphous or fine pleomorphic calcifications Nondescript solid mass with indistinct margins
Slide 61-

Category 4c New group of fine linear calcifications New indistinct, irregular solitary mass.
Slide 62-

The CC mammographic image shows a finding, not reproducible on the MLO view. This finding is sufficiently suspicious to JUSTIFY A BIOPSY A
Slide 63-

The pathologist could report to you that it is sclerosing adenosis or ductal carcinoma in situ. Both diagnoses are concordant with the mammographic findings.
Slide 64-

BI-RADS 5 Highly Suggestive of Malignancy. Appropriate Action Should Be Taken. The current rationale for using category 5 is that if the percutaneous tissue diagnosis is nonmalignant, this automatically should be considered as discordant
Slide 65-

LESIONS INCLUDE Use of combination of highly suspicious findings are present: Spiculated, irregular highdensity mass. Segmental or linear arrangement of fine linear calcifications. Irregular spiculated mass with associated pleomorphic calcifications.
Slide 66-

ppt slide no 66 content not found
Slide 67-

ppt slide no 67 content not found
Slide 68-

ppt slide no 68 content not found
Slide 69-

BI-RADS 6 Use after incomplete excision Use after monitoring response to neoadjuvant chemotherapy Don't use after attempted surgical excision with positive margins and no imaging findings other than postsurgical scarring. Then use category 2 and add sentence stating the absence of mammographic correlate for the pathology.
Slide 70-

ppt slide no 70 content not found
Slide 71-

On the initial mammogram a marker is placed in the palpable tumor. Due to the dense fibroglandular tissue the tumor is not well seen. Ultrasound demonstrated a 37 mm mass with indistinct and angular margins and shadowing
Slide 72-

BREAST MRI Magnetic resonance imaging (MRI) uses repeated radiofrequency pulses in concert with precise spatial modulation of a strong magnetic field to image the distribution and nuclear magnetic resonance characteristics of hydrogen atoms within human tissue
Slide 73-

Accepted Indications for Contrast- Enhanced Breast MRI SCREENING ACS recommendations BRCA mutation (BRCA1 or BRCA2) First-degree relative of BRCA carrier, but untested Lifetime risk of approximately 20% to 25% or greater, as defined by BRCAPRO or other models that are largely dependent on family history Obscured breast tissue (e.g., previous free silicone injection) Radiation to chest between age 10 and 30 (e.g., for Hodgkin disease) Li-Fraumeni syndrome (p53 mutation) and firstdegree relatives Cowden and Bannayan-Riley-Ruvalcaba syndromes and first-degree relatives
Slide 74-

DIAGNOSIS Suspicious lesions seen on only one x-ray mammographic view, not found by sonography Bloody nipple discharge with negative or failed galactogram Indeterminate palpable findings with negative mammogram and ultrasound
Slide 75-

STAGING Locate the breast primary in patients with axillary metastases Detect chest wall invasion Evaluate opposite breast in patients with new, unilateral breast cancer Evaluate the extent of cancer in patients with poorly evaluated breast tissue on mammography: Dense breasts Implants, free silicone injection Evaluate the extent of cancer in tumors poorly seen on mammography Infiltrating lobular carcinoma Ductal carcinoma in situ without corresponding microcalcifications Goals of breast cancer staging MRI: Plan lumpectomy to reduce the rate of transected tumor at specimen margins Detect occult multifocal or multicentric tumor Detect occult contralateral tumor Detect residual disease when initial lumpectomy is incomplete
Slide 76-

MANAGEMENT (ESPECIALLY PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY) Measure disease before initiating neoadjuvant chemotherapy. Assess response to treatment after the initial cycle. Localize potential residual tumor after a complete clinical response.
Slide 77-

Basic Bilateral Protocol for Breast Cancer MRI Axial T1 or STIR Show lymph nodes and overall anatomy; localization 2 Fast T2* Map cysts, ducts; assess lesion T2 Diffusion-weighted EPI† Assess lesion ADC 3-D T1 fat-saturated spoiled gradient echo; 90 seconds or less Baseline prior to contrast injection Repeat series 4 over 7–12 min with contrast Assess contrast enhancement morphology and kinetics 1H spectroscopy Measure choline Postprocessing Enhancement curves, subtraction, 3-D, measurements, parametric maps
Slide 78-

CONTRAST ENHANCEMENT Contrast-enhanced MRI is extremely sensitive for tumor angiogenesis, regardless of radiographic breast density. Tumor angiogenesis leads to preferential enhancement of cancers with intravenous contrast. Lesion morphology helps distinguish cancer from benign conditions. The time-course of contrast enhancement helps distinguish invasive cancer from other conditions
Slide 79-

No enhancement (type I) or gradual enhancement (type II) suggests a benign lesion. Rapid initial enhancement followed by gradual late enhancement (type III) is indeterminate. Rapid initial enhancement followed by a plateau signal intensity (type IV) or early washout of signal intensity (type V) is suspicious for invasive malignancy
Slide 80-

Morphologic Features of Enhancing Breast Lesions FEATURES SUGGESTING BENIGNANCY Minimal enhancement Smooth or gently lobulated margin Most intense enhancement at center Homogeneous enhancement Nonenhancing internal septations Oriented along Cooper ligaments
Slide 81-

ppt slide no 81 content not found
Slide 82-

FEATURES SUGGESTING MALIGNANCY Bright enhancement Spiculated, very irregular margin Rim enhancement Heterogeneous enhancement Enhancing septations Ductal/linear-branching/segmental enhancement Associated enhancement of adjacent tissue region Enlarged feeding blood vessel
Slide 83-

ppt slide no 83 content not found
Slide 84-

Very high signal on T2-weighted fast spin-echo images that is brighter than fat (on nonfat-suppressed sequences) and substantially brighter than glandular tissue suggests a benign lesion such as a cyst (A, arrow), intramammary lymph node (B, arrows), or fibroadenoma (C).
Slide 85-

Most malignancies, unless frankly necrotic, have a signal intensity that is similar to that of fibroglandular tissue
Slide 86-

PET CT The fundamental strength of PET over conventional imaging is the ability to convey functional information that even the most exquisitely detailed anatomic image cannot provide. The standard PET radiotracer in current clinical use, FDG is a glucose analog that is taken up by cells in proportion to their rate of glucose metabolism. The increased glycolytic rate and glucose avidity of malignant cells in comparison to normal tissue is the basis of the ability of FDG-PET imaging to accurately differentiate cancer from benign tissue regardless of morphology
Slide 87-

As of June 2009, the Centers for Medicare & Medicaid Services (CMS) approves of coverage for FDG-PET scanning for the following indications in breast cancer: As an adjunct to standard imaging modalities for staging patients with distant metastasis or restaging patients with locoregional recurrence of metastasis; as an adjunct to standard imaging modalities for monitoring tumor response to treatment for women with locally advanced and metastatic breast cancer when a change in therapy is anticipated
Slide 88-

Initial Diagnosis Although noninvasive breast cancer has been previously shown to be poorly imaged by FDG- PET), the majority of FDG-PET studies in the literature have been performed on patients with invasive breast cancer
Slide 89-

Initial Staging The performance of FDG-PET imaging in breast cancer staging can be separated into two general categories: staging of axillary lymph nodes, in which use of PET has met with decidedly mixed results, and staging of mediastinal and internal mammary lymph nodes and distant metastatic disease, in which FDG-PET has consistently performed well.
Slide 90-

ppt slide no 90 content not found
Slide 91-

THANK YOU